ENANTA PHARMACEUTICA
ENTA
 Delayed - 01/22 04:00:00 pm |
|
| 47.67USD | +1.84% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Biotechnology & Medical Research | |||
| Biotechnology & Medical Research | |||
| Biotechnology & Medical Research - NEC | |||
Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.
Number of employees : 141 people.
Number of employees : 141 people.
Sales per Business
| 2019 | 2020 | |||
| USD (in Million) | % | USD (in Million) | % | |
| Small Molecule Drugs | 205.20 | 100% | 122.47 | 100% |
Sales per region
| 2019 | 2020 | |||
| USD (in Million) | % | USD (in Million) | % | |
| United States | 205.20 | 100% | 122.47 | 100% |
Managers
| Name | Title |
| Jay R. Luly | President, Chief Executive Officer & Director |
| Bruce Leonard Andrews Carter | Non-Executive Chairman |
| Paul J. Mellett | CFO & Senior VP-Finance & Administration |
| Yat Sun Or | CSO, Senior Vice President-Research & Development |
| Nathalie Adda | Chief Medical Officer & Senior Vice President |
| Terry C. Vance | Lead Independent Director |
| George S. Golumbeski | Independent Director |
| Lesley Russell | Independent Director |
| Kristine Peterson | Independent Director |
| Mark G. Foletta | Independent Director |
| Shareholders |
| Name | Equities | % |
| Farallon Capital Management LLC | 1,775,000 | 8.84% |
| The Vanguard Group, Inc. | 1,688,702 | 8.41% |
| Apex Capital Management, Inc. | 1,292,751 | 6.44% |
| Alan J. Dworsky | 1,209,773 | 6.03% |
| Renaissance Technologies LLC | 1,029,000 | 5.12% |
| Eagle Asset Management, Inc. | 1,001,572 | 4.99% |
| T. Rowe Price Associates, Inc. (Investment Management) | 974,429 | 4.85% |
| SSgA Funds Management, Inc. | 963,518 | 4.80% |
| Krensavage Asset Management LLC | 825,329 | 4.11% |
| BlackRock Fund Advisors | 700,412 | 3.49% |
Company contact information
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472
Phone : +1.617.607.0800
Fax : +1.617.607.0530
Web : http://www.enanta.com
500 Arsenal Street
Watertown, MA 02472
Phone : +1.617.607.0800
Fax : +1.617.607.0530
Web : http://www.enanta.com
Sector Biotechnology & Medical Research - NEC
| 1st jan. | Capi. (M$) | ||
 | |||
| ENANTA PHARMACEUTICALS, INC. | 13.23% | 960 | |
| |||
| MODERNA, INC. | 25.41% | 51 846 | |
| LONZA GROUP AG | 5.34% | 50 271 | |
| CELLTRION, INC. | -13.65% | 38 245 | |
| IQVIA HOLDINGS INC. | 3.58% | 35 582 | |
| SEAGEN INC. | 4.35% | 33 059 | |
| HANGZHOU TIGERMED CONSULTING CO.,LTD | 13.79% | 24 266 | |
| INCYTE CORPORATION | 7.96% | 21 438 | |
| ALNYLAM PHARMACEUTICALS, INC. | 32.63% | 20 027 | |
| PHARMARON BEIJING CO., LTD. | 29.82% | 18 864 | |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 12.56% | 13 937 | |
| CRISPR THERAPEUTICS AG | 23.11% | 13 932 | |
| BIO-TECHNE CORPORATION | 12.29% | 13 768 | |
| QIAGEN N.V. | 2.80% | 12 355 | |
| PPD, INC. | 1.99% | 12 203 | |
| ICON PUBLIC LIMITED COMPANY | 10.90% | 11 412 | |
| IONIS PHARMACEUTICALS, INC. | 9.21% | 8 634 | |
| PRA HEALTH SCIENCES, INC. | 5.44% | 8 484 | |
| ACADIA PHARMACEUTICALS INC. | -1.18% | 8 399 | |
| SYNEOS HEALTH, INC. | 11.68% | 7 907 | |
| UNITED THERAPEUTICS CORPORATION | 10.49% | 7 453 | |
